ライフサイエンスコーパス: axillary lymph node

1 needle aspiration of a palpable, ipsilateral axillary lymph node.

2 at the cellular level until they entered the axillary lymph node.

3 nel lymph node biopsy, and 10 had a positive axillary lymph node.

4 mapping, and only one patient had a positive axillary lymph node.

5 The margins are negative, as are all 11 axillary lymph nodes.

6 breast cancer who underwent US assessment of axillary lymph nodes.

7 in the spleen and in inguinal, brachial, and axillary lymph nodes.

8 o residual invasive cancer in the breast and axillary lymph nodes.

9 the regional spread of breast cancer to the axillary lymph nodes.

10 evidence of invasive tumor in the breast and axillary lymph nodes.

11 age breast cancer without involvement of the axillary lymph nodes.

12 idence of invasive disease in the breast and axillary lymph nodes.

13 imary breast cancer and at least 10 involved axillary lymph nodes.

14 of these patients had residual tumor within axillary lymph nodes.

15 ancer patients, independent of the status of axillary lymph nodes.

16 ly 3 cm on exam, and multiple palpable right axillary lymph nodes.

17 wall and/or the ipsilateral supraclavicular/axillary lymph nodes.

18 multiple conglomerated 1-2 cm level I and II axillary lymph nodes.

19 t cancer patients with four or more involved axillary lymph nodes.

20 umor cells are unlikely to be found in other axillary lymph nodes.

21 mographic screening (elsewhere) had negative axillary lymph nodes.

22 istologic characteristics of the rest of the axillary lymph nodes.

23 ologic complete response (pCR) in breast and axillary lymph nodes.

24 absence of invasive cancer in the breast and axillary lymph nodes.

25 y measuring time to peak signal intensity in axillary lymph nodes.

26 even lesions in the neck, five (55%) of nine axillary lymph nodes, 11 (50%) of 22 bone metastases, an

27 < .001) and had a larger number of involved axillary lymph nodes (41% v 26% had > 3 involved nodes;

28 stology) as did other features (27% positive axillary lymph nodes, 63% positive estrogen receptors, a

29 Of women with positive axillary lymph nodes, 83% aged less than 51 years and 52

30 f 20 primary breast tumors and their matched axillary lymph nodes, a high concordance (Fisher's exact

31 accurate exclusion of clinically significant axillary lymph node (ALN) disease.

32 tients achieving pCR of cytologically proven axillary lymph node (ALN) metastases.

33 ession in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differ

34 Pathologic axillary lymph node (ALN) status is an important prognos

35 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

36 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

37 iption polymerase chain reaction (RT-PCR) in axillary lymph nodes (ALN) of breast cancer patients.

38 therapy in patients with 10 or more positive axillary lymph nodes (ALN) to reduce the high loco-regio

39 A was prominently expressed in the liver and axillary lymph nodes, although preliminary data suggest

40 bsence of invasive disease in the breast and axillary lymph nodes, analysed by intention to treat.

41 -10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with

42 all survival based on the number of positive axillary lymph nodes and (in N0 patients) pathologic tum

43 perable breast cancer involving four or more axillary lymph nodes and had completed mastectomy or bre

44 icant incidence of metastatic disease to the axillary lymph nodes and may benefit most from selective

45 h biopsy-proved metastatic adenocarcinoma to axillary lymph nodes and occult primary tumor underwent

46 tion is that patients who develop disease in axillary lymph nodes and subsequently undergo ALND have

47 ed significantly with the number of positive axillary lymph nodes and with postchemotherapy c-erbB-2

48 iltrating lobular carcinoma in the breast or axillary lymph nodes) and 12-month follow-up.

49 nd intraductal disease in the breast and the axillary lymph nodes), and the safety of adding bevacizu

50 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes on e

51 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes.

52 etween radiotracer uptake in spleen, tonsil, axillary lymph nodes, and peripheral blood CD4 T-cell co

53 n of lymph node status by number of involved axillary lymph nodes; and new classifications for metast

54 gn transport of breast epithelial cells into axillary lymph nodes are recently described phenomena.

55 Our group has shown that nonsentinel axillary lymph nodes are unlikely to contain tumor cells

56 ith combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR, decreased from

57 ne of five Ontario study centers followed by axillary lymph node assessment (ALNA) consisting of sent

58 tients diagnosed with at least four positive axillary lymph nodes at diagnosis who underwent anthracy

59 in women who had more than three metastatic axillary lymph nodes at the time of diagnosis.

60 g NHPs had significant (18)FDG uptake in the axillary lymph nodes at the time of MPXV challenge with

61 elevated D-dimer (> 100 ng/mL) and involved axillary lymph nodes (chi(2) test; P =.001).

62 excision of the tumour (1 cm margin) and an axillary lymph-node clearance or sample, all patients re

63 ion took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-r

64 ns of macrophages isolated from the spleens, axillary lymph nodes, colons, jejuna, and livers of heal

65 Two of the 11 axillary lymph nodes contained metastatic carcinoma.

66 P < .001), high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more sev

67 cer diagnosis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt

68 relative risk, 0.83 [CI, 0.77 to 0.90]) and axillary lymph node dissection (adjusted relative risk,

69 n with breast cancer, the role of completion axillary lymph node dissection (ALND) after identificati

70 Axillary lymph node dissection (ALND) as part of surgica

71 SLNB has replaced axillary lymph node dissection (ALND) as the staging mod

72 staging information with less morbidity than axillary lymph node dissection (ALND) for patients with

73 node biopsy (SLNB) was developed to replace axillary lymph node dissection (ALND) for staging early

74 Axillary lymph node dissection (ALND) has been a part of

75 Axillary lymph node dissection (ALND) has been a standar

76 lymph nodes (SLNs) were negative, SLNB with axillary lymph node dissection (ALND) if SLNB or PET was

77 For breast cancer patients, the role of the axillary lymph node dissection (ALND) in the management

78 Recent enthusiasm for limiting axillary lymph node dissection (ALND) in women with brea

79 l lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to

80 ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in

81 n both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of

82 itivity for macrometastasis (Ma), leading to axillary lymph node dissection (ALND) only when strictly

83 hat consisted of either total mastectomy and axillary lymph node dissection (ALND) or segmental maste

84 inel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph

85 In all cases with a tumor-involved SN, axillary lymph node dissection (ALND) was recommended.

86 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

87 e predicted that 20 to 30 cases of SLND with axillary lymph node dissection (ALND) would enable surge

88 trolled trial in which SNB was compared with axillary lymph node dissection (ALND), four limited meta

89 orized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

90 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

91 mph nodes (SLNs) who did and did not undergo axillary lymph node dissection (ALND).

92 lymphedema (BCRL) in patients who underwent axillary lymph node dissection (ALND).

93 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

94 with a positive SLN who underwent completion axillary lymph node dissection (ALND).

95 e categorized in 4 groups: SLN-negative with axillary lymph node dissection (ALND; n = 326), SLN-nega

96 ph nodes (SLNs) generally undergo completion axillary lymph node dissection (cALND), either concurren

97 included body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymp

98 Axillary lymph node dissection (P < 0.0001), higher body

99 SLN biopsy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/ALND) between June

100 opsy (SLNB) alone and after SLNB followed by axillary lymph node dissection (SLNB/ALND).

101 results (sentinel lymph node biopsy [SNB] or axillary lymph node dissection [ALND]) were compared wit

102 2 patients were randomly assigned to receive axillary lymph node dissection and 2404 to receive axill

103 inel node, 744 had been randomly assigned to axillary lymph node dissection and 681 to axillary radio

104 Axillary lymph node dissection and axillary radiotherapy

105 Breast-conserving surgery combined with axillary lymph node dissection and radiotherapy or maste

106 d the localized lymph node before completion axillary lymph node dissection and used radiography of t

107 For selected patients, axillary lymph node dissection appears to have little in

108 er were significantly less likely to receive axillary lymph node dissection as determined by logistic

109 Axillary lymph node dissection can identify the presence

110 lar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior

111 me progressively less extensive, with formal axillary lymph node dissection confined to a dwindling g

112 Axillary lymph node dissection continues to be routinely

113 y useful for intraoperative or postoperative axillary lymph node dissection decisions.

114 ence occurred in four of 744 patients in the axillary lymph node dissection group and seven of 681 in

115 In the axillary lymph node dissection group, 220 (33%) of 672 p

116 py group compared with an expected 2% in the axillary lymph node dissection group.

117 oup, 220 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive n

118 ymph nodes (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (

119 east cancers while avoiding the morbidity of axillary lymph node dissection if the nodes do not conta

120 gest that it is time to reassess the role of axillary lymph node dissection in patients who undergo c

121 Indications for omission of completion axillary lymph node dissection in patients with two or f

122 These findings do not support routine use of axillary lymph node dissection in this patient populatio

123 Of the 59 patients, 48 had axillary lymph node dissection irrespective of the resul

124 Complete axillary lymph node dissection is indicated in patients

125 st cancer who have a positive sentinel node, axillary lymph node dissection is the present standard.

126 This suggests that axillary lymph node dissection may not be necessary in p

127 erated allocation schedule to receive either axillary lymph node dissection or axillary radiotherapy

128 Although axillary lymph node dissection provides excellent region

129 arm was noted significantly more often after axillary lymph node dissection than after axillary radio

130 SLN biopsy followed by completion level I/II axillary lymph node dissection to determine the false-ne

131 ecurrence was 0.43% (95% CI 0.00-0.92) after axillary lymph node dissection versus 1.19% (0.31-2.08)

132 A complementary axillary lymph node dissection was performed in all pati

133 patients undergoing total mastectomy and/or axillary lymph node dissection were randomized to standa

134 the ability to achieve the results of total axillary lymph node dissection without the risks of surg

135 bility to obtain prognostic information (ie, axillary lymph node dissection), tends to minimize treat

136 e, approximately 10% of women do not have an axillary lymph node dissection, 11% to 26% do not have t

137 .4% underwent an initial SLNB, 37.2% initial axillary lymph node dissection, and 6.3% no axillary sur

138 eoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate

139 andard primary tumor therapy, to not receive axillary lymph node dissection, and to not receive radia

140 We have previously found that axillary lymph node dissection, both clinically and in a

141 Two patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for

142 y, followed by breast-conserving surgery and axillary lymph node dissection, which revealed residual

143 rm morbidity and better quality of life than axillary lymph node dissection.

144 authors examined receipt of radiotherapy and axillary lymph node dissection.

145 All patients were offered axillary lymph node dissection.

146 ents in the initial group went on to undergo axillary lymph node dissection.

147 the unnecessary complications of a complete axillary lymph node dissection.

148 ents would have been spared the morbidity of axillary lymph node dissection.

149 s of any size continue to mandate completion axillary lymph node dissection.

150 is an accurate, less invasive alternative to axillary lymph node dissection.

151 of NAC, all patients had breast surgery with axillary lymph node dissection.

152 either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection.

153 r to overall survival for those treated with axillary lymph node dissection.

154 ocal recurrence rate and similar survival to axillary lymph node dissection.Preoperative axillary ult

155 y, because a separate incision is needed for axillary lymph-node dissection, and postoperative radiot

156 The goals of axillary-lymph-node dissection (ALND) are to maximise su

157 rgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND).

158 sentinel-lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replace

159 The previously undisputed gold standard of axillary-lymph-node dissection for staging has now been

160 on the present role and routine practice of axillary-lymph-node dissection in early breast cancer, t

161 h-node biopsy, but also lymph-node sampling, axillary-lymph-node dissection, and observation alone.

162 s practice pattern could lead to unnecessary axillary lymph node dissections and lymphedema.

163 e, 36-79 years) with breast cancer before 52 axillary lymph node dissections.

164 Despite guidelines recommending against axillary lymph node evaluation in women with DCIS underg

165 Although axillary lymph node evaluation is standard of care in th

166 Axillary lymph node examination revealed residual tumor

167 Invasive cancers that had spread to axillary lymph nodes exhibited higher SF content than di

168 strated equally well in benign and malignant axillary lymph nodes for all three groups.

169 strated that SLN biopsy can be used to stage axillary lymph nodes for breast cancer.

170 (US)-guided fine-needle aspiration (FNA) of axillary lymph nodes for preoperative staging of breast

171 ty of catecholaminergic neural fibers within axillary lymph nodes from adult rhesus macaques.

172 ns of the HEVs are also characterized in the axillary lymph nodes from human breast cancer patients w

173 ize averaged 5.7 cm with clinically positive axillary lymph nodes in 23 patients (57%).

174 The MDA-MB-231 cells metastasized to axillary lymph nodes in a SCID mouse model.

175 US-guided FNA of axillary lymph nodes in patients with newly diagnosed br

176 y breast tumors resulted in viral transit to axillary lymph nodes, infection of lymphatic metastases,

177 Patients and physicians should tailor axillary lymph node interventions to maximize regional d

178 rder interactions were considered: number of axillary lymph nodes involved (zero v one to three v fou

179 years or older without prior chemotherapy or axillary lymph node involvement and (2) the hypofraction

180 Axillary lymph node involvement in breast cancer is a ma

181 , age, comorbid disease, prior chemotherapy, axillary lymph node involvement, intensity-modulated rad

182 and micrometastasis to the SLN had remaining axillary lymph node involvement.

183 50 years or those with prior chemotherapy or axillary lymph node involvement.

184 munohistochemical examination of ipsilateral axillary lymph nodes is a reliable, prognostically valua

185 Reliable pathologic stage classification of axillary lymph nodes is an important determinant of prog

186 rimary breast cancer and 10 or more involved axillary lymph nodes is poor.

187 d cervical lymph nodes but fewer than 20% of axillary lymph nodes, livers, brown fat samples, kidneys

188 group included 17 patients with ipsilateral axillary lymph node (LN) metastases.

189 of 2.68 +/- 1.0 mm between FMT and SPECT for axillary lymph node localization.

190 Axillary lymph nodes marked with a clip can be localized

191 had a breast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

192 Axillary lymph node metastases are most significantly re

193 There were axillary lymph node metastases in four samples (9%).

194 Patients with axillary lymph node metastases may benefit from postmast

195 h negative PET scans had such a low risk for axillary lymph node metastases that axillary dissection

196 The rate of axillary lymph node metastases was consistent with SLN t

197 d with a 1% to 3% reduction in recurrence of axillary lymph node metastases, but is associated with a

198 the 181 patients with lymphatic invasion had axillary lymph node metastases, compared with 19% of the

199 ive breast carcinomas and is associated with axillary lymph node metastases.

200 hy, and can also make it difficult to detect axillary lymph node metastases.

201 as inversely correlated with the presence of axillary lymph node metastases.

202 tify variables independently associated with axillary lymph node metastases.

203 imary human breast carcinomas and associated axillary lymph node metastases.

204 serve as a cost-effective screening test for axillary lymph node metastases.

205 -1 ratio was observed in primary tumors with axillary lymph node metastasis than in node-negative tum

206 y into nude mice, the primary tumor volumes, axillary lymph node metastasis, and lung metastasis were

207 nfiltrating ductal carcinomas; and one (2%), axillary lymph node metastasis.

208 primary tumor subclones, or subclones in an axillary lymph node metastasis.

209 t to substitute it for SLNB for exclusion of axillary lymph node metastasis.

210 ease recurrence in a cohort of patients with axillary lymph node-negative breast cancer.

211 ion of chromosome 14q 31.2 is much higher in axillary lymph node-negative primary breast tumors than

212 d ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard rat

213 uding internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole

214 ot sufficiently sensitive to detect positive axillary lymph nodes, nor is it sufficiently specific to

215 LNs removed, no cancer was identified in the axillary lymph nodes of 215 patients, yielding a patholo

216 to those in spleen, IL-10-positive cells in axillary lymph nodes of coinfected animals were predomin

217 capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery.

218 to stimulate CD4(+) T cells derived from the axillary lymph nodes of mice vaccinated with irradiated

219 Methylene blue dye accumulation in axillary lymph nodes of seven healthy Sprague-Dawley rat

220 s, primary tumors and contralateral positive axillary lymph nodes, or two ipsilateral tumors).

221 rative activity in a cohort of patients with axillary lymph node-positive breast cancer and compare t

222 identification of a subset of patients with axillary lymph node-positive breast cancer with an impro

223 We enrolled 4950 women with axillary lymph node-positive or high-risk, lymph node-ne

224 A subset of axillary lymph node-positive patients with improved prog

225 node-negative primary breast tumors than in axillary lymph node-positive primary breast tumors.

226 Premenopausal women with axillary lymph node-positive, steroid hormone receptor-p

227 Injection of recombinant SLC in the axillary lymph node region led to a marked reduction in

228 IA) during transport from the forepaw to the axillary lymph node region of a rat.

229 for drainage into the cervical, inguinal, or axillary lymph nodes, respectively.

230 tumor response was predictive of a complete axillary lymph node response (P<.01 ).

231 The existing standard for axillary lymph node staging in breast cancer patients wi

232 or accurate, noninvasive imaging of SLNs for axillary lymph node staging in breast cancer patients.

233 SLN biopsy is a new standard of care for axillary lymph node staging in breast cancer.

234 When performed, pathologic axillary lymph node staging was node-negative (n=86).

235 Axillary lymph node status is the most important factor

236 Axillary lymph node status is the single most important

237 However, tumor size and axillary lymph node status were clearly superior prognos

238 In contrast, histology and axillary lymph node status were significant predictors o

239 growth factor receptor 2 (HER2) status; and axillary lymph node status with chi(2) or Fisher exact t

240 o age, stage, tumor site, tumor size, grade, axillary lymph node status, extent of surgery, and radio

241 r site, tumor size, grade, ER and PR status, axillary lymph node status, extent of surgery, and RT, t

242 s were analyzed in relation to the patients' axillary lymph node status, menopausal status, disease s

243 Axillary lymph node status, site of relapse, and hormone

244 stic parameter independent of tumor size and axillary lymph node status.

245 ias was not observed in the non-gut-draining axillary lymph nodes, suggesting that the Th17 bias was

246 cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adj

247 tion system (balanced for number of involved axillary lymph nodes, tumour stage, oestrogen receptor s

248 nomas, and metastatic breast carcinomas from axillary lymph nodes using quantitative TaqMan reverse t

249 A tumor-positive axillary lymph node was marked with a I seed in 100 pati

250 US-guided 14-gauge CNB of abnormal axillary lymph nodes was performed in 100 of 144 patient

251 Axillary lymph nodes were analyzed using an in vivo fluo

252 ases in primary breast-cancer patients whose axillary lymph nodes were classified, by conventional me

253 for breast cancer confined to the breast and axillary lymph nodes were entered in a prospective study

254 Lymphadenopathy and immune activation in the axillary lymph nodes were evident in IV- and IB-infected

255 Primary tumors and involved axillary lymph nodes were identified, and the [(18)F]-FD

256 Prior to NST, proven tumor-positive axillary lymph nodes were marked with a I seed.

257 ongly with disease-specific survival whether axillary lymph nodes were negative or positive for metas

258 , or IIIA breast cancer involving 10 or more axillary lymph nodes were randomized after surgery and s

259 ng mammography, asymmetrically enlarged left axillary lymph nodes were seen in a healthy 70-year-old

260 st cancer involving four or more ipsilateral axillary lymph nodes were treated with nine cycles of ch

261 The MARI procedure [marking the axillary lymph node with radioactive iodine (I) seeds] i

262 Axillary lymph nodes with abnormal US findings can be sa

263 an occult metastatic melanoma involving the axillary lymph nodes with an unknown primary site.